The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) is a huge mover today! About 183,748 shares traded hands. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 57.79% since March 7, 2016 and is uptrending. It has outperformed by 50.20% the S&P500.
The move comes after 8 months positive chart setup for the $759.93 million company. It was reported on Oct, 10 by Barchart.com. We have $10.26 PT which if reached, will make NASDAQ:CORT worth $379.97 million more.
Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on November, 3. CORT’s profit will be $2.22 million for 85.50 P/E if the $0.02 EPS becomes a reality. After $0.02 actual EPS reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.”
Insitutional Activity: The institutional sentiment increased to 1.8 in 2016 Q2. Its up 0.57, from 1.23 in 2016Q1. The ratio increased, as 13 funds sold all Corcept Therapeutics Incorporated shares owned while 22 reduced positions. 24 funds bought stakes while 39 increased positions. They now own 45.31 million shares or 34.44% more from 33.70 million shares in 2016Q1.
Deutsche Commercial Bank Ag holds 11,417 shares or 0% of its portfolio. New York State Common Retirement Fund owns 76,400 shares or 0% of their US portfolio. Legal And General Grp Plc last reported 0% of its portfolio in the stock. Principal Fin Group has 14,878 shares for 0% of their US portfolio. First Eagle Inv Ltd Liability holds 223,935 shares or 0% of its portfolio. Panagora Asset Inc last reported 10,387 shares in the company. Bancorp Of America Corp De has 0% invested in the company for 30,692 shares. The New York-based Gabelli Incorporated has invested 0.07% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Spark Invest Mgmt holds 104,400 shares or 0.05% of its portfolio. Investor Ab, a Sweden-based fund reported 1.84 million shares. Rhumbline Advisers last reported 0% of its portfolio in the stock. Invesco Limited has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Teachers Advisors holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 118,135 shares. Evanson Asset Mgmt Ltd owns 22,800 shares or 0.04% of their US portfolio. Renaissance Technology Limited owns 310,600 shares or 0% of their US portfolio.
Insider Transactions: Since May 6, 2016, the stock had 1 insider purchase, and 0 insider sales for $487,895 net activity. BAKER G LEONARD JR had bought 100,000 shares worth $487,895.
More recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Fool.com which released: “Corcept Therapeutics Rose 18% in March. Here’s Why.” on April 06, 2016. Also Fool.com published the news titled: “Why Corcept Therapeutics Incorporated Shares Were Mauled” on May 07, 2014. Finance.Yahoo.com‘s news article titled: “Zacks.com featured highlights: Corcept Therapeutics, Parsley Energy, TRI …” with publication date: September 06, 2016 was also an interesting one.
CORT Company Profile
Corcept Therapeutics Inc., incorporated on May 13, 1998, is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). The Firm also has discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. The Firm has begun pre-clinical and clinical development of its lead compounds from these series.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.